薬物発見のための分子ドッキングにおけるディープラーニングの限界を解読する
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。ディープラーニング (DL) は薬剤設計のための分子ドッキングを強化しますが,現実世界のアプリケーションでは課題が残っています. 生成型モデルは精度が優れているが,多様なタンパク質の標的に対する一般化は限られており,さらなる最適化が必要である.
科学分野
- 計算化学と化学情報学
- 薬剤開発における人工知能
- 構造生物学と分子モデリング
背景
- 構造に基づく分子ドッキングは コンピューターによる薬物の設計に不可欠です
- ディープラーニング (DL) はドッキングに革命を起こしていますが,翻訳に課題があります.
- 伝統的なアプローチと比較してDLドッキング方法を評価することは不可欠です.
研究 の 目的
- 伝統的な分子ドッキング方法と DL による分子ドッキング方法を包括的に評価する.
- ポーズ予測,物理的妥当性,相互作用回復,仮想スクリーニング (VS) の有効性,および一般化におけるパフォーマンスを分析する.
- DLドッキングフレームワークの限界を特定し,最適化戦略を提案する.
主な方法
- 伝統的なドッキングとDLパラダイム (生成的拡散,回帰,ハイブリッド) の比較分析.
- 精度,妥当性,回復性,VS有効性,一般化といった5つの重要な性能面での評価.
- 失敗メカニズムの調査と最適化戦略の探索.
主要な成果
- ジェネラティブ・ディフュージョン・モデルでは,ポーズ予測の精度が高く,ハイブリッド・メソッドはバランスの取れたパフォーマンスを提供します.
- 回帰モデルは,物理的に不合理なポーズを生成する.ほとんどのDL方法は,高いステリック耐性を示す.
- 特に新しいタンパク質結合ポケットで,現在のDLの適用性を制限する重要な一般化課題が観察されました.
結論
- DLは分子ドッキングに大きく影響し,生成モデルは精度が優れています.
- 現在のDL方法は物理的な妥当性や一般化の限界に直面し,広範な適用を妨げています.
- 信頼性の高い<i>in silico</i>薬剤設計のための堅牢で一般化可能なDLフレームワークを開発するには,さらなる研究が必要です.
関連する概念動画
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
where P and L are the unbound protein and ligand, respectively, and PL is the protein-ligand complex.
As the amount of bound ligand is also related to the rate of ligand binding, experiments can also determine Kb by examining the rates of protein-ligand association (kon) and dissociation (koff) using the following ratio:
Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...